Megan Garlapow, PhD

Contributing Writer https://www.cancertherapyadvisor.com

Megan Garlapow, PhD, is the principal and owner of The Line Medical Communications, LLC. Garlapow has worked across a wide variety of projects and therapeutic areas. She holds a BA in biology from the University of Chicago and a PhD in genetics from North Carolina State University. Before working as a medical writer, Garlapow worked in a biopsychology lab, examining social factors affecting breast cancer in rats and people and in a neurogenetics lab, examining the circadian factors affecting nicotine addiction in a mouse model. In her PhD, she used quantitative genetics approaches to examine the regulation of feeding. Her postdoctoral research at Arizona State University focused on environmental and genetic factors affecting body weight. You can find her on LinkedIn at https://www.linkedin.com/in/megangarlapow/

All articles by Megan Garlapow, PhD

No differences in overall survival time and quality of life in elderly and/or frail patients with ne

Lung Cancer

SBRT for Elderly Patients With Unresectable Lung Cancer

Megan Garlapow, PhD

March 20, 2017

SBRT may be an effective strategy for elderly patients with unresectable lung cancer.

Recent studies attempted to improve the risk of recurrence while reducing the risk of adverse effect

Lung Cancer

Reirradiation of Thoracic Cancers Provides Disease Control and Minimal Toxicity

Megan Garlapow, PhD

March 20, 2017

Definitive reirradiation of thoracic cancers with IMPT can provide durable local control with minimal toxicity and can extend survival.

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal

Lung Cancer

Circulating Tumor Cell Monitoring Offers Early Prediction of Recurrent NSCLC

Megan Garlapow, PhD

March 17, 2017

Post-radiotherapy samples in 20 of 22 recurrences revealed that 15 of these patients (75%) had an increase in CTC counts.

PET-CT guided active surveillance results in substantially fewer complications in locally advanced H

Lung Cancer

Combining Radiotherapy and Immunotherapy: Adverse Events in Lung Cancer

Megan Garlapow, PhD

March 17, 2017

In an analysis of metastatic lung cancer treated with thoracic radiotherapy and immunotherapy, 3 patients had severe toxicity.

Recent advances in immunotherapy preceded the approval of programmed cell death 1 (PD-1) inhibitors

Lung Cancer

Genetic Variations and Therapy Resistance in EGFR-mutant NSCLC

Megan Garlapow, PhD

March 17, 2017

Resistance to EGFR-targeted therapies may not be permanent; a single biopsy is insufficient for fully understanding the nature of therapy resistance.

Researchers recently created a tool, Treeomics, to reconstruct the evolutionary pathway of metastase

General Oncology

Treeomics: A Mathematical Tool for Predicting Metastases

Megan Garlapow, PhD

March 8, 2017

Researchers recently created a tool, Treeomics, to reconstruct the evolutionary pathway of metastases and to chart subclones to their anatomical locations.